Wednesday, July 8, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 7, 2026
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
background ▾
- •Congressional scrutiny of Big Pharma clinical trial operations in Xinjiang escalated with formal letters alleging human rights violations and potential diversion of trial data to Chinese military biotechnology programs.
- •Multiple U.S. and European drugmakers (J&J, Eli Lilly, Amgen, Regeneron, Bayer, Novartis) and Chinese biotech partners operate trials in the region, suggesting sector-wide exposure to regulatory and reputational risk.
- •Watch for: Congressional follow-up actions, potential amendments to the COINS Act restricting China investments, regulatory guidance from FDA on trial site eligibility, and how pharma companies restructure China trial strategies in response.
PfizerMerck & Co.Bristol Myers Squibb
→ Read original articlePolicy•KFF•Jul 8, 2026
In Preliminary Rate Filings, ACA Marketplace Insurers Largely Propose Double-Digit Premium Increase For 2027, Following a Steep Climb This Year
background ▾
- •Median 14% premium increase proposed for 2027 would represent cumulative >33% increase over 2025-2027, signaling sustained affordability pressure in ACA individual markets
- •Expiration of enhanced premium tax credits is explicitly cited as a cost driver, indicating potential policy headwinds without Congressional action to extend subsidies
- •Preliminary filings cover only 16 states plus DC; final nationwide picture emerges after July 15 deadline, with potential for significant variation in regional rate trajectories
Policy•STAT News•Jul 8, 2026
Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
background ▾
- •FDA cleared Dexcom Stelo for OTC use in children ≥2 years old, marking the first prescription-free CGM approval for pediatrics in the U.S. and significantly expanding market access
- •Expert opinion is mixed: some endocrinologists view OTC CGMs as improving access for underserved high-risk populations, while pediatricians and eating disorder specialists warn of potential harms including anxiety, disordered eating patterns, and 'wellness culture' spillover to children
- •Competitive implications: other CGM manufacturers (Abbott, Medtronic, Senseonics) will likely pursue similar pediatric OTC clearances, with regulatory precedent now established
DexcomAbbottMedtronicDexcom SteloDexcom G7
→ Read original articlePolicy•STAT News•Jul 8, 2026
Opinion: The AI licensure debate is missing the point of licensure
background ▾
- •Medical licensure's core function is establishing personal, legal, and fiduciary accountability for clinical outcomes—not merely credentialing—and this cannot be transferred to AI systems or corporate actors
- •Current AI deployment fragments accountability: vendors, health systems, and payers capture economic value while physicians retain full legal liability if patient harm occurs
- •Established case law (Dent v. West Virginia, Hawker v. New York, Canterbury v. Spence, Shinal v. Toms) establishes that clinical decision-making duties are nondelegable and remain with the physician regardless of technology intermediaries
Policy•STAT News•Jul 8, 2026
Opinion: STAT+: What’s the right role for AI in dementia care?
background ▾
- •AI chatbots may address caregiver burden and patient boredom in dementia care by providing meaningful conversational engagement
Market Access
Market Access•Fierce Biotech•Jul 8, 2026
AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre
background ▾
- •AstraZeneca is betting $2.1B to directly compete with Merck's Ohtuvayre (which generated $131M in Q1 2024 alone) using a challenger with potentially superior early efficacy data
- •TQC3721's phase 2 FEV1 improvement of 147 mL exceeds Verona's historical phase 2 benchmark (124 mL), suggesting potential best-in-class positioning, but this remains unvalidated in phase 3
- •Watch for: TQC3721 phase 3 readout timelines in China and AstraZeneca's regulatory strategy for Western markets; concurrent advancement of tozorakimab (anti-IL-33) and AZD6793 (IRAK4i) will determine AstraZeneca's depth in next-generation COPD
AstraZenecaSino BiopharmaceuticalChia Tai Tianqing PharmaceuticalTQC3721OhtuvayreSymbicort
→ Read original articleMarket Access•Fierce Biotech•Jul 7, 2026
MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
background ▾
- •MeiraGTx secured $400M from Oberland Capital (initial $125M plus royalties) to commercialize two gene therapies despite bota-vec's phase 3 miss on primary endpoint, signaling investor confidence in secondary efficacy data and market opportunity
- •Both candidates target rare diseases with high unmet need and could reach approval within 12-24 months; company also advancing AAV-GAD for Parkinson's disease with promising phase 2 data
- •Watch for regulatory decisions on bota-vec and AAV2-hAQP1, particularly whether FDA will accept bota-vec filing despite primary endpoint failure, and readout of AQUAx2 phase 2 trial (expected end of 2025) which unlocks additional $50M
MeiraGTxOberland CapitalJohnson & Johnsonbotaretigene sparoparvovec (bota-vec)AAV2-hAQP1AAV-GAD
→ Read original articleMarket Access•Fierce Biotech•Jul 7, 2026
Whitehawk swoops in for five ADCs via development deal with China's Biocytogen
background ▾
- •Whitehawk is systematically building an ADC pipeline through multiple partnerships (now including Biocytogen, WuXi Biologics, and Hangzhou DAC), positioning itself as an ADC platform company rather than a single-asset developer
- •Biocytogen continues to expand its ADC collaboration footprint beyond 2024's high-value deals (Ideaya $400M, Sotio $326M), indicating strong market demand for its bispecific antibody capabilities
Whitehawk TherapeuticsBiocytogenWuXi Biologics
→ Read original articleMarket Access•Endpoints News•Jul 7, 2026
Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader
background ▾
- •Vertex's $10 billion Crinetics acquisition represents a transformative M&A move to diversify away from its CF-dependent revenue base and establish platform capabilities in endocrinology
- •The deal demonstrates Vertex's confidence in its CF cash generation to fund major external innovation while competing with larger diversified pharma peers
- •Monitor Vertex's ability to integrate Crinetics operations, advance its endocrinology pipeline, and maintain CF market leadership during the transition period
Vertex PharmaceuticalsCrinetics Pharmaceuticals
→ Read original articleMarket Access•Fierce Biotech•Jul 7, 2026
Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay
background ▾
- •Beckman Coulter's CE-marked Access p-Tau217 assay brings a validated Alzheimer's biomarker into routine European clinical practice, enabling lab-based scalability of blood testing for disease pathology assessment
- •The assay uses AlzPath's pTau217 antibody, which has supporting evidence from 200+ peer-reviewed publications, enhancing clinical credibility
- •This move directly follows Abbott's announcement of a partnership with ALZpath for competing pTau217 diagnostic development, signaling intensifying competition in blood-based Alzheimer's diagnostics
Beckman CoulterAlzPathAbbottAccess p-Tau217Access BD-pTau217
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 7, 2026
Boehringer bags PVT’s viral vector platform for cancer vaccine R&D
background ▾
- •Boehringer is diversifying its oncolytic virus portfolio beyond its struggling VSV-GP program (phase 1 recently suspended) by acquiring ORFV platform rights, signaling confidence in viral vector oncology despite recent setbacks.
- •PVT's COVID-19 program served as critical proof-of-concept for ORFV manufacturing and human safety, removing historical barriers to development in cancer—this de-risking was likely key to Boehringer's investment decision.
- •Watch for: Boehringer's first IND filing with ORFV-based cancer vaccine candidate; clinical readout of VSV-GP phase 1 data and rationale for trial suspension; whether competing ORFV programs emerge from other manufacturers.
Boehringer IngelheimPrime Vector TechnologiesAmgenORFV platformPrime-2-CoVImlygic
→ Read original articleClinical Trials•Fierce Biotech•Jul 7, 2026
Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical
background ▾
- •Novo Nordisk is advancing a novel long-acting semaglutide implant (NPM-139) designed to address patient preference for less frequent dosing, a potential competitive differentiator against Eli Lilly's aggressive GLP-1 market expansion.
- •Phase 1 initiation is imminent, making this a near-term clinical catalyst for the semaglutide franchise; the lack of exclusivity provisions suggests Vivani's platform may be available to other pharma partners.
- •Monitor phase 1 efficacy, safety, and pharmacokinetic data; assess whether long-acting implant formulation can improve patient adherence and retention versus current injectable competitors.
Novo NordiskVivani MedicalEli LillysemaglutideWegovyOzempic
→ Read original articleClinical Trials•Fierce Biotech•Jul 7, 2026
Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials
background ▾
- •HRS-7535 achieved 10.9–11.1% weight loss in obesity trials, matching competitor benchmarks but with significantly higher gastrointestinal adverse event rates (70% nausea, 68.6% vomiting vs. 24–47% for Foundayo and Wegovy)
- •Efficacy in Type 2 diabetes confirmed with HbA1c reductions up to 1.68%, exceeding the SGLT2 inhibitor comparator dapagliflozin (1.28%)
- •Watch for Kailera's phase 2 obesity data readout expected in 2025 and Hengrui's regulatory submission timeline in China; tolerability profile will be critical to market differentiation in an increasingly crowded oral GLP-1 landscape
Kailera TherapeuticsHengrui PharmaEli LillyHRS-7535KAI-7535Foundayo
→ Read original articleClinical Trials•Endpoints News•Jul 7, 2026
Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
background ▾
- •Compass's psilocybin treatment maintained efficacy through at least six months follow-up in its second pivotal trial, a critical durability endpoint for a single-dose depression therapy
- •Year-end regulatory filing planned, marking the first potential FDA approval of a psilocybin-based drug if successful
- •Watch for FDA decision on approval timeline and any additional post-marketing study requirements given the novel mechanism and limited long-term safety data in depression
Compass PathwaysCOMP360psilocybin
→ Read original articleClinical Trials•Endpoints News•Jul 7, 2026
Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
background ▾
- •Oral GLP-1 showed efficacy in late-stage China trials but with notably higher adverse event rates than typically seen with injectable comparators, presenting a potential clinical and commercial liability
- •China-based trials suggest the companies are pursuing regional development strategy, likely capitalizing on market access and patient population advantages in Asia before potential global expansion
- •Safety profile and dose tolerability will be critical determinants of whether this candidate can differentiate in a crowded GLP-1 market dominated by well-tolerated injectable agents (semaglutide, tirzepatide)
Hengrui PharmaKailera TherapeuticsGLP-1 receptor agonist (oral formulation, candidate identity not disclosed in article)
→ Read original article